Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, showcasing significant growth across key metrics and markets.

Financial Highlights

• Revenue reached Rs. 3,178.00 crores, marking an 11% year-over-year increase
• Operating EBITDA grew by 14% to Rs. 1,032.00 crores
• Net profit after tax surged by 20% to Rs. 548.00 crores
• R&D spend increased by 16% to Rs. 157.00 crores, representing 5% of revenue

Strong Performance Across Markets

India

• India revenues rose by 11% to Rs. 1,811.00 crores, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%
• Chronic business grew by 13%, compared to IPM growth of 9% in this segment
• 21 brands featured in the Top 500 IPM brands, with 14 brands exceeding Rs. 100.00 crores in sales

Brazil

• Brazil revenues increased by 11% to Rs. 218.00 crores
• Constant currency revenues grew by 16% to R$ 143.00 million
• Torrent's growth of 14% outpaced the market growth of 5%
• 62 products are currently under review by ANVISA, Brazil's health regulatory agency

Germany

• Germany revenues grew by 9% to Rs. 308.00 crores
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party supplier

United States

• US business revenues surged by 19% to Rs. 308.00 crores
• Constant currency revenues increased by 16% to $36.00 million
• Recent product launches have achieved targeted market shares

Financial Position and Profitability

The company maintained strong profitability metrics:

Net profit margin improved from 16.00% in the same quarter last year.

Strategic Developments

Torrent Pharmaceuticals has entered into a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The proposed transaction, subject to regulatory approvals, will be executed in two phases:

1. Acquisition of up to 74.80% equity stake in JB Pharma through a combination of direct purchase and an open offer
2. Subsequent merger of JB Pharma with Torrent Pharmaceuticals

This strategic move is expected to strengthen Torrent's position in the Indian pharmaceutical market.

Research and Development

Torrent Pharma continues to invest heavily in R&D, with spending reaching Rs. 157.00 crores in Q1, representing 5% of revenue. The company's focus on innovation is evident in its product pipeline and market performance.

Conclusion

Torrent Pharmaceuticals' Q1 results demonstrate the company's strong growth trajectory and operational efficiency. With robust performance across key markets, strategic expansion plans, and continued focus on R&D, Torrent Pharma is well-positioned for sustained growth in the competitive pharmaceutical landscape.

Note: All financial figures are in Indian Rupees (INR) unless otherwise stated.

Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, demonstrating strong growth across its key markets and therapeutic segments.

Financial Highlights

• Revenue from operations increased by 11% year-over-year to Rs. 3,178.00 crores
• Operating EBITDA grew by 14% to Rs. 1,032.00 crores, with a margin of 32.5%
• Net profit after tax surged by 20% to Rs. 548.00 crores
• R&D expenditure stood at Rs. 157.00 crores, representing 5% of revenue

Market Performance

India

The company's performance in its home market remained strong:

• India revenues rose by 11% to Rs. 1,811.00 crores
• Chronic business grew by 13%, outpacing the Indian Pharmaceutical Market (IPM) growth of 9%
• Torrent now has 21 brands in the Top 500 brands in IPM, with 14 brands generating over Rs. 100.00 crores in sales

International Markets

Torrent Pharma also reported solid growth in its key international markets:

Operational Performance

The company's gross margin remained stable at 76%, while the operating EBITDA margin improved slightly to 32.5%. Notably, the reported operating EBITDA includes acquisition-related one-off expenses of Rs. 15.00 crores. Adjusting for these one-time costs, the operating EBITDA stands at Rs. 1,047.00 crores with a margin of 32.9%.

R&D and Product Pipeline

Torrent Pharmaceuticals continues to invest significantly in research and development:

• R&D spending increased by 16% year-over-year to Rs. 157.00 crores
• The company has 62 products under review by ANVISA (Brazilian Health Regulatory Agency)

Market Position

Torrent Pharma has strengthened its position in key therapeutic segments:

• Ranked 7th in the Indian Pharmaceuticals Market
• Among the Top 5 in Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Cosmo-Dermatology segments
• Approximately 76% of its India revenues come from chronic and sub-chronic therapies

Global Presence

The company has expanded its global footprint:

• Present in over 50 countries
• Ranked No. 1 amongst Indian pharma companies in Brazil and Germany
• Operates 8 manufacturing facilities, including 5 USFDA-approved sites

Torrent Pharmaceuticals' strong performance reflects its robust product portfolio, strategic market presence, and continued focus on research and development. The company's ability to outperform market growth in key segments and geographies positions it well for sustained growth in the coming quarters.